临床试验设计中的关键问题（精神病学）
2013-08-01 MedSci MedSci原创
n general. To improve and validate a scale, or to develop a new one, is a daunting task that often exceeds the capabilities of the individual investigator. The pharmaceutical industry spon
n general. To improve and validate a scale, or to develop a new one, is a daunting task that often exceeds the capabilities of the individual investigator. The pharmaceutical industry sponsor of a new drug is similarly limited in ability to create a new outcome measure that might be more optimal for novel drugs. Data based on proven instruments are required in a New Drug Application (NDA). Outcome data derived from a new rating scale would be regarded as supplemental evidence only. The emphasis
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
#精神病学#
43
#关键问题#
39